TY - JOUR
T1 - Perceived utility and disutility of genomic sequencing for pediatric patients
T2 - Perspectives from parents with diverse sociodemographic characteristics
AU - Undiagnosed Diseases Network
AU - Halley, Meghan C.
AU - Young, Jennifer L.
AU - Fernandez, Liliana
AU - Kohler, Jennefer N.
AU - Bernstein, Jonathan A.
AU - Wheeler, Matthew T.
AU - Tabor, Holly K.
N1 - Funding Information:
Research reported in this manuscript was supported in part by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number U01HG010218, and by a grant from the Stanford Maternal & Child Health Research Institute, award number 1233211‐102‐JHAJL. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Stanford Maternal & Child Health Research Institute.
Funding Information:
Research reported in this manuscript was supported in part by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number U01HG010218, and by a grant from the Stanford Maternal & Child Health Research Institute, award number 1233211-102-JHAJL. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Stanford Maternal & Child Health Research Institute. Effort for M.C.H. was supported by K01HG011341, 3U01HG010218-03S2 and UL1TR003142-02. Effort for H.K.T. was provided by 3U01HG010218-03S2 and 5UL1TR003142-02. Effort for J.L.Y. was supported by T32HG008953. The authors thank the participants and families in the Undiagnosed Diseases Network for sharing their stories, and Emily Miller for technical support.
Funding Information:
Effort for M.C.H. was supported by K01HG011341, 3U01HG010218‐03S2 and UL1TR003142‐02. Effort for H.K.T. was provided by 3U01HG010218‐03S2 and 5UL1TR003142‐02. Effort for J.L.Y. was supported by T32HG008953. The authors thank the participants and families in the Undiagnosed Diseases Network for sharing their stories, and Emily Miller for technical support.
Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022/4
Y1 - 2022/4
N2 - Given the limited therapeutic options for most rare diseases diagnosed through genomic sequencing (GS) and the proportion of patients who remain undiagnosed even after GS, it is important to characterize a broader range of benefits and potential harms of GS from the perspectives of families with diverse sociodemographic characteristics. We recruited parents of children enrolled in the Undiagnosed Diseases Network. Parents completed an in-depth interview, and we conducted a comparative content analysis of the data. Parents (n = 30) were demographically diverse, with 43.3% identifying as Hispanic, 33.3% primarily Spanish-speaking, and widely variable household income and education. Parents reported minimal changes in their child's health status following GS but did report a range of other forms of perceived utility, including improvements in their child's healthcare management and access, in their own psychological well-being, and in disease-specific social connections and research opportunities. Parents who received a diagnosis more frequently perceived utility across all domains; however, disutility also was reported by both those with and without a diagnosis. Impacts depended on multiple mediating factors, including parents' underlying expectations and beliefs, family sociodemographic characteristics, individual disease characteristics, and prior healthcare access. Our study suggests that the perceived utility of GS varies widely among parents and may depend on multiple individual, sociodemographic, and contextual factors that are relevant for pre- and post-GS counseling, for value assessment of GS, and for policymaking related to access to new genomic technologies.
AB - Given the limited therapeutic options for most rare diseases diagnosed through genomic sequencing (GS) and the proportion of patients who remain undiagnosed even after GS, it is important to characterize a broader range of benefits and potential harms of GS from the perspectives of families with diverse sociodemographic characteristics. We recruited parents of children enrolled in the Undiagnosed Diseases Network. Parents completed an in-depth interview, and we conducted a comparative content analysis of the data. Parents (n = 30) were demographically diverse, with 43.3% identifying as Hispanic, 33.3% primarily Spanish-speaking, and widely variable household income and education. Parents reported minimal changes in their child's health status following GS but did report a range of other forms of perceived utility, including improvements in their child's healthcare management and access, in their own psychological well-being, and in disease-specific social connections and research opportunities. Parents who received a diagnosis more frequently perceived utility across all domains; however, disutility also was reported by both those with and without a diagnosis. Impacts depended on multiple mediating factors, including parents' underlying expectations and beliefs, family sociodemographic characteristics, individual disease characteristics, and prior healthcare access. Our study suggests that the perceived utility of GS varies widely among parents and may depend on multiple individual, sociodemographic, and contextual factors that are relevant for pre- and post-GS counseling, for value assessment of GS, and for policymaking related to access to new genomic technologies.
KW - genome sequencing
KW - health disparities
KW - pediatrics
KW - perceived utility
KW - personal utility
KW - rare disease
UR - http://www.scopus.com/inward/record.url?scp=85122335461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122335461&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.62619
DO - 10.1002/ajmg.a.62619
M3 - Article
C2 - 34981646
AN - SCOPUS:85122335461
SN - 1552-4825
VL - 188
SP - 1088
EP - 1101
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 4
ER -